XVII CONGRESSO MINEIRO DE PNEUMOLOGIA E CIRURGIA TORÁCICA e VI CONGRESSO MINEIRO DE PNEUMOLOGIA PEDIÁTRICA
1º Dia - 10/10/25
2º Dia - 10/11/25
3º Dia - 10/9/25

Avanços no Tratamento do Grupo III Voltar

Rodrigo Luis Barbosa Lima

Mesa Redonda - Tratamento da Hipertensão Pulmonar - Ricardo Amorim

Artigo Autor(es) Referência
Clinical trials in group 3 pulmonary hypertension. Harder Eileen M, Waxman Aaron B Current opinion in pulmonary medicine. 2020 Sep; 26(Sep):391-396. doi: 10.1097/MCP.0000000000000694. pii: .
Group 3 Pulmonary Hypertension: From Bench to Bedside. Singh Navneet, Dorfmüller Peter, Shlobin Oksana A, Ventetuolo Corey E Circulation research. 2022 04; 130(04):1404-1422. doi: 10.1161/CIRCRESAHA.121.319970. pii: .
Group 3 pulmonary hypertension: Challenges and opportunities. McGettrick Michael, Peacock Andrew Global cardiology science & practice. 2020 Apr; 2020(Apr):e202006. doi: 10.21542/gcsp.2020.6. pii: .
Inhaled treprostinil in group 3 pulmonary hypertension associated with lung disease: results of the INCREASE and PERFECT studies. Cullivan Sarah, Genecand Leon, El-Merhie Natalia, MacKenzie Alison, Lichtblau Mona Breathe (Sheffield, England). 2025 Jan; 21(Jan):240242. doi: 10.1183/20734735.0242-2024. pii: 240242.
Lung Disease-Related Pulmonary Hypertension. Ahmad Kareem, Khangoora Vikramjit, Nathan Steven D Cardiology clinics. 2022 Feb; 40(Feb):77-88. doi: 10.1016/j.ccl.2021.08.005. pii: S0733-8651(21)00068-0.
New trends in pulmonary hypertension. Cullivan Sarah, Gaine Sean, Sitbon Olivier European respiratory review : an official journal of the European Respiratory Society. 2023 Mar; 32(Mar):doi: 10.1183/16000617.0211-2022. pii: 220211.
Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease. Gonzales Janae, Fraidenburg Dustin R Pharmaceuticals (Basel, Switzerland). 2023 Mar; 16(Mar):doi: 10.3390/ph16030418. pii: 418.
Practical considerations in the management of inhaled prostacyclin therapy for pulmonary hypertension associated with interstitial lung disease (WHO group 3). Lee Charlie, Hamlyn Joan, Porcelli Julie, Schmit Ann Respiratory medicine. 2022 Mar; 196(Mar):106806. doi: 10.1016/j.rmed.2022.106806. pii: S0954-6111(22)00071-3.
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD): Back to the Future. Fiorentù Giordano, Bernardinello Nicol, Giulianelli Giacomo, Cocconcelli Elisabetta, Balestro Elisabetta, Spagnolo Paolo Advances in therapy. 2025 Feb; doi: 10.1007/s12325-025-03129-3. pii: .
Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension. Shlobin Oksana A, Shen Eric, Wort Stephen J, Piccari Lucilla, Scandurra John A, Hassoun Paul M, Nikkho Sylvia M, Nathan Steven D Pulmonary circulation. 2024 Jan; 14(Jan):e12310. doi: 10.1002/pul2.12310. pii: e12310.
Shifting gears: the search for group 3 pulmonary hypertension treatment. Keen Jennifer L, Thenappan Thenappan Current opinion in pulmonary medicine. 2021 Jul; doi: 10.1097/MCP.0000000000000788. pii: .
The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment. King Christopher S, Shlobin Oksana A Chest. 2020 10; 158(10):1651-1664. doi: 10.1016/j.chest.2020.04.046. pii: S0012-3692(20)30872-2.
Nenhuma revista foi definida para este congresso.